Effect of Acute Ketamine Treatment on Sympathetic Regulation Indexed by Electrodermal Activity in Adolescent Major Depression

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2024 Mar 28

PMID 38543144

Authors

Veronika Kovacova

Andrea Macejova

Ingrid Tonhajzerova

Zuzana Visnovcova

Nikola Ferencova

Zuzana Mlyncekova

Tomas Kukucka

Ivan Farsky

Slavomir Nosal

Igor Ondrejka

Affiliations

Soon will be listed here.

Abstract

Ketamine is a potential rapid-onset antidepressant characterized by sympathomimetic effects. However, the question of ketamine's use in treating adolescents' major depressive disorder (MDD) is still discussed. Thus, we aimed to study the acute effect of ketamine infusion treatment on sympathetic regulation using electrodermal activity (EDA) in addition to an assessment of depressive symptomatology in MDD adolescents. Twenty hospitalized adolescent girls with MDD (average age: 15.0 ± 1.46 yrs.) were examined before and two hours after a single intravenous infusion of ketamine. EDA was continuously recorded for 6 min, and depressive symptoms were assessed before and two hours after ketamine administration. The evaluated parameters included skin conductance level (SCL), nonspecific electrodermal responses (NS-SCRs), MADRS (questions no. 1-10, total score), and CDI (items A-E, total score). EDA parameters showed no significant changes after the ketamine treatment, and depressive symptoms were significantly reduced after the ketamine infusion. The analysis revealed a significant negative correlation between index SCL and CDI-A, CDI-E, and the total CDI score and between index NS-SCRs and MADRS no. 4 before the ketamine treatment. In conclusion, ketamine improved depressive symptomatology without a significant effect on EDA, indicating its potential safety and efficiency as an acute antidepressant intervention in adolescent MDD.

References

Hirota K, Lambert D . Anaesthesia-related drugs and SARS-CoV-2 infection. Br J Anaesth. 2021; 127(1):e32-e34. PMC: 8020093. DOI: 10.1016/j.bja.2021.03.026. View

Seeman P, Ko F, Tallerico T . Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics. Mol Psychiatry. 2005; 10(9):877-83. DOI: 10.1038/sj.mp.4001682. View

Rottenberg J, Gross J, Wilhelm F, Najmi S, Gotlib I . Crying threshold and intensity in major depressive disorder. J Abnorm Psychol. 2002; 111(2):302-12. View

Kohrs R, Durieux M . Ketamine: teaching an old drug new tricks. Anesth Analg. 1998; 87(5):1186-93. DOI: 10.1097/00000539-199811000-00039. View

Schmitz A, Theurillat R, Lassahn P, Mevissen M, Thormann W . CE provides evidence of the stereoselective hydroxylation of norketamine in equines. Electrophoresis. 2009; 30(16):2912-21. DOI: 10.1002/elps.200900221. View

Durieux M . Inhibition by ketamine of muscarinic acetylcholine receptor function. Anesth Analg. 1995; 81(1):57-62. DOI: 10.1097/00000539-199507000-00012. View

Singh B, Kung S, Pazdernik V, Schak K, Geske J, Schulte P . Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study. J Clin Psychiatry. 2023; 84(2). DOI: 10.4088/JCP.22m14548. View

Mion G, Villevieille T . Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013; 19(6):370-80. PMC: 6493357. DOI: 10.1111/cns.12099. View

Edginton A, Schmitt W, Voith B, Willmann S . A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006; 45(7):683-704. DOI: 10.2165/00003088-200645070-00004. View

10.

Herd D, Anderson B . Ketamine disposition in children presenting for procedural sedation and analgesia in a children's emergency department. Paediatr Anaesth. 2007; 17(7):622-9. DOI: 10.1111/j.1460-9592.2006.02145.x. View

11.

Liebe T, Li S, Lord A, Colic L, Krause A, Batra A . Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. Int J Neuropsychopharmacol. 2017; 20(11):909-918. PMC: 5737852. DOI: 10.1093/ijnp/pyx055. View

12.

Charkoudian N, Rabbitts J . Sympathetic neural mechanisms in human cardiovascular health and disease. Mayo Clin Proc. 2009; 84(9):822-30. PMC: 2735432. DOI: 10.4065/84.9.822. View

13.

Dinis-Oliveira R . Metabolism and metabolomics of ketamine: a toxicological approach. Forensic Sci Res. 2018; 2(1):2-10. PMC: 6197107. DOI: 10.1080/20961790.2017.1285219. View

14.

Posada-Quintero H, Florian J, Orjuela-Canon A, Aljama-Corrales T, Charleston-Villalobos S, Chon K . Power Spectral Density Analysis of Electrodermal Activity for Sympathetic Function Assessment. Ann Biomed Eng. 2016; 44(10):3124-3135. DOI: 10.1007/s10439-016-1606-6. View

15.

Tsai J, Pole N, Levenson R, Munoz R . The effects of depression on the emotional responses of Spanish-speaking Latinas. Cultur Divers Ethnic Minor Psychol. 2003; 9(1):49-63. DOI: 10.1037/1099-9809.9.1.49. View

16.

Mendelowitz D . Advances in Parasympathetic Control of Heart Rate and Cardiac Function. News Physiol Sci. 2001; 14:155-161. DOI: 10.1152/physiologyonline.1999.14.4.155. View

17.

Harteveld L, Nederend I, Ten Harkel A, Schutte N, de Rooij S, Vrijkotte T . Maturation of the Cardiac Autonomic Nervous System Activity in Children and Adolescents. J Am Heart Assoc. 2021; 10(4):e017405. PMC: 7955328. DOI: 10.1161/JAHA.120.017405. View

18.

Okamoto H, Hoka S, Kawasaki T, Okuyama T, Takahashi S . L-arginine attenuates ketamine-induced increase in renal sympathetic nerve activity. Anesthesiology. 1994; 81(1):137-46. DOI: 10.1097/00000542-199407000-00020. View

19.

Maalouf F, Atwi M, Brent D . Treatment-resistant depression in adolescents: review and updates on clinical management. Depress Anxiety. 2011; 28(11):946-54. DOI: 10.1002/da.20884. View

20.

Smucker M, Craighead W, Craighead L, Green B . Normative and reliability data for the Children's Depression Inventory. J Abnorm Child Psychol. 1986; 14(1):25-39. DOI: 10.1007/BF00917219. View